RadioMedix
RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation.
Overview
RadioMedix, based in Houston, is developing AlphaMedix, or 212Pb-DOTAMTATE, with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation. AlphaMedix met all primary efficacy endpoints in phase 2, with a 60 percent objective response rate in PRRT-naive gastroenteropancreatic neuroendocrine tumour patients reported at ESMO 2025, was licensed to Sanofi with Orano Med in 2024, and has its next trial planned for late 2026; the company marked twenty years at SNMMI 2026. Nuclide links it to neuroendocrine tumours, to targeted alpha therapy and peptide receptor radionuclide therapy, to somatostatin receptor 2 as a target, and to Orano Med and Sanofi. Whether a lead-212 alpha emitter beats existing beta-emitter PRRT in a randomised trial is the open question. 212Pb-DOTAMTATE has its own page.
Scorecard
All companies- approved products +12
- phase 1/2 +1
- targets +4
- modalities +4
- regions +6
- 24-month regulatory events +2
- registry trials +9
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-09-12 | RadioMedix to Sanofi AlphaMedix (lead-212 DOTAMTATE), targeted alpha therapy for neuroendocrine tumours | Licence | €100m | up to €220m in sales milestones plus tiered royalties | source |
Manufacturing
Capacity map- Orano Med Plano Plano, Texas, US · Orano MedRadioisotope production, Radiopharmaceutical manufacturing
An alpha-particle version of neuroendocrine radioligand therapy that produced responses in over half of patients who had never had PRRT, with FDA Breakthrough designation.
An injectable tracer that sticks to a marker (somatostatin receptor) many neuroendocrine tumours carry. A PET scan afterwards shows where those tumours are, including small deposits that other scans can miss.
Gallium-68 PSMA-11 was the first PSMA PET tracer approved in the US (2020), and is made on site from a generator or cyclotron.
Similar pages
not linked directly; found by shared links- TrialALPHAMEDIX-02
Shares 212Pb-DOTAMTATE, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Lead-212, Peptide receptor radionuclide therapy (PRRT).
- AgentLead-212 VMT-alpha-NET
Shares 212Pb-DOTAMTATE, Lead-212, Somatostatin receptor 2, Targeted alpha therapy.
- TrialStudy of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Shares Orano Med, Lead-212, Neuroendocrine tumours.
- PairingBeta PRRT → alpha PRRT
Shares 212Pb-DOTAMTATE, Lead-212, Targeted alpha therapy, Neuroendocrine tumours.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT), Neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Lead-212, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy.
- TechnologyAlpha-emitter daughter redistribution ('free daughter' problem)
Shares 212Pb-DOTAMTATE, Lead-212, Targeted alpha therapy.
- RoadmapSSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha
Shares 212Pb-DOTAMTATE, Lead-212, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).